First Quadrant L P CA grew its stake in shares of Catalent Inc (NASDAQ:CTLT) by 6,276.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 135,951 shares of the company’s stock after purchasing an additional 133,819 shares during the quarter. First Quadrant L P CA owned approximately 0.11% of Catalent worth $5,427,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new position in shares of Catalent during the second quarter worth approximately $239,629,000. BlackRock Inc. boosted its position in shares of Catalent by 15.2% during the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the period. AJO LP acquired a new position in shares of Catalent during the second quarter worth approximately $26,130,000. Macquarie Group Ltd. boosted its position in shares of Catalent by 60.2% during the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after buying an additional 671,429 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Catalent during the second quarter worth approximately $23,092,000.

Shares of Catalent Inc (NASDAQ:CTLT) opened at 42.59 on Wednesday. The company has a market capitalization of $5.33 billion and a PE ratio of 48.95. Catalent Inc has a one year low of $21.83 and a one year high of $43.39. The company has a 50-day moving average of $41.37 and a 200-day moving average of $36.56.

Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.08. The company had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a net margin of 10.02% and a return on equity of 36.29%. Catalent’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 EPS. On average, analysts anticipate that Catalent Inc will post $1.63 earnings per share for the current year.

Several equities analysts have recently issued reports on CTLT shares. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research report on Tuesday, August 22nd. BidaskClub upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. William Blair reaffirmed an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. Bank of America Corporation reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Catalent currently has an average rating of “Buy” and an average target price of $41.67.

In other news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total transaction of $61,767.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/11/01/first-quadrant-l-p-ca-buys-133819-shares-of-catalent-inc-ctlt.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Institutional Ownership by Quarter for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.